Advanced Breast Cancer

Michael Untch; Peter A. Fasching; Renate Haidinger; Nadia Harbeck; Christian Jackisch; Diana Lüftner; Volkmar Müller; Eva Schumacher-Wulf; Rachel Würstlein; Christoph Thomssen

doi:10.1055/a-1904-6100

Geburtshilfe und Frauenheilkunde, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2022; 82(10): 1044-1054
DOI: 10.1055/a-1904-6100

GebFra Science

Review/Übersicht

Advanced Breast Cancer

AGO Recommendations 2022 – Focus on ABC6 Consensus Artikel in mehreren Sprachen: English | deutsch

Michael Untch

¹Klinik für Gynäkologie und Geburtshilfe, Multidisziplinäres Brustzentrum und Zentrum für gynäkologische Onkologie, HELIOS Klinikum Berlin Buch, Berlin, Germany

,

Peter A. Fasching

²Universitätsfrauenklinik Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

,

Renate Haidinger

³Brustkrebs Deutschland e. V., Hohenbrunn, Germany; Patientenvertreterin, ABC6-Ko-Vorsitz, ABC-Panelistin

,

Nadia Harbeck

⁴Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Comprehensive Cancer Center (CCC) München, LMU Klinikum, München, Germany; ABC-Panelistin

,

Christian Jackisch

⁵Klinik für Gynäkologie und Geburtshilfe, Sana Klinikum Offenbach GmbH, Offenbach, Germany

,

Diana Lüftner

⁶Immanuel Klinik Märkische Schweiz, Medizinische Hochschule Brandenburg Theodor-Fontane, Buckow, Germany

,

Volkmar Müller

⁷Universitätsklinik für Gynäkologie, Hamburg-Eppendorf, Hamburg, Germany

,

Eva Schumacher-Wulf

⁸Mamma Mia! Brustkrebsmagazin, Köln, Germany; Patientenvertreterin

,

Rachel Würstlein

⁹Brustzentrum, Klinik und Poliklinik für Frauenheilkunde und Comprehensive Cancer Center (CCC) München, LMU Klinikum, München, Germany

,

Christoph Thomssen

¹⁰Universitätsfrauenklinik, Martin-Luther-Universität, Halle an der Saale, Germany; ABC-Panelist

› Institutsangaben

Abstract

Over the past few years, there have been many developments in the treatment of advanced breast cancer; these have been incorporated into national and international treatment guidelines, resulting in an improved prognosis for these patients. The 6th International Consensus Conference for Advanced Breast Cancer (ABC6) was held in November 2021. The aim is to standardize the treatment of advanced breast cancer based on a high level of evidence, and to make new treatment options accessible to all patients. In this article we discuss the ABC6 consensus in the context of German treatment guidelines, and compare it with clinical practice in Germany. The authors refer to the current recommendations of the Breast Cancer Working Group for Gynecological Oncology (AGO Mamma) published in March 2022. The AGO Breast Cancer Guidelines are updated annually. Since discrepancies between national and international guidelines can occur due to country-specific regulations, this is a useful comparison to make. The German authors refer to the voting results of the ABC6 panelists from 6 November 2021.

Key words

advanced breast cancer - systemic therapy - treatment sequencing - oligometastasis - brain metastases - supportive treatment

Volltext

Referenzen

References/Literatur
1 AGO Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome (März 2022). Accessed April 01, 2022 at: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
2 Thill M, Lüftner D, Kolberg-Liedtke C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care (Basel) 2022;
3 Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001; 33: 139-144
4 Bruckmann NM, Kirchner J, Umutlu L. et al. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol 2021; 31: 8714-8724
5 Morawitz J, Bruckmann N-M, Dietzel F. et al. Comparison of nodal staging between CT, MRI, and 18F‑FDG PET/MRI in patients with newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2021;
6 Schmid P. KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC (16.07.2021). Zugriff am 22. April 2022 unter: https://www.esmo.org/meetings/keynote-522-phase-iii-study-of-neoadjuvant-chemotherapy-vs-placebo-chemotherapy-followed-by-adjuvant-vs-placebo-for-early-stage-tnbc?hit=ehp
7 Schneeweiss A, Chia S, Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278-2284
8 Tutt A, Garber JE, Kaufman B. et al. OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. J Clin Oncol 2021; 39: LBA1
9 Soran A, Ozmen V, Ozbas S. et al. Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial. J Am Coll Surg 2021; 233: 742-751.e5
10 Palma DA, Olson R, Harrow S. et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol 2020; 38: 2830-2838
11 Nash AL, Thomas SM, Plichta JK. et al. Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?. Ann Surg Oncol 2021; 28: 5544-5552
12 Foley NM, Coll JM, Lowery AJ. et al. Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?. Pathol Oncol Res 2018; 24: 881-884
13 Park YH, Kim T-Y, Kim GM. et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2019; 20: 1750-1759
14 Martin M, Zielinski C, Ruiz-Borrego M. et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol 2021; 32: 488-499
15 André F, Ciruelos EM, Juric D. et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021; 32: 208-217
16 Rugo HS, Lerebours F, Ciruelos E. et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 2021; 22: 489-498
17 DeMichele A, Clark AS, Tan KS. et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 2015; 21: 995-1001
18 Cortés J, Kim SB, Chung WP. et al. DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154
19 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
20 Gennari A, André F, Barrios CH. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;
21 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621
22 Bardia A, Hurvitz SA, Tolaney SM. et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529-1541
23 Tung NM, Robson ME, Ventz S. et al. TBCRC048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 2020; 38: 4274-4282
24 Robson ME, Tung N, Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianʼs choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30: 558-566
25 Litton JK, Hurvitz SA, Mina LA. et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 2020; 31: 1526-1535
26 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121
27 Cortes J, Cescon DW, Rugo HS. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817-1828
28 von Minckwitz G, Huang C-S, Mano MS. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628
29 Montemurro F, Delaloge S, Barrios CH. et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase III b clinical trial☆. Ann Oncol 2020; 31: 1350-1358
30 Deutsche Gesellschaft für Palliativmedizin. S3-Leitlinie Palliativmedizin. Accessed November 19, 2021 at: https://www.dgpalliativmedizin.de/images/stories/pdf/LL_Palliativmedizin_Langversion_2.2.pdf
31 Deutsche Gesellschaft für Supportivmedizin. S3-Leitlinie Supportiv Therapie bei onkologischen Patienten – AWMF. Accessed November 19, 2021 at: https://www.awmf.org/uploads/tx_szleitlinien/032-054OLl_S3_Supportiv_2020-07.pdf
32 Loeser AL, Peppercorn JM, Burkard ME. et al. Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC). J Clin Oncol 2021; 39: 1005